Webinars and Sponsored Roundtables — Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.

Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Marketplace

Henry Schein, CytoChip enter distribution agreement

March 2026—Henry Schein entered into an exclusive distribution agreement with CytoChip for CitoCBC, a 510(k)-cleared, CLIA-waived, cartridge-based CBC system. CitoCBC uses blood collected in a venous draw tube to analyze 16 parameters, including the five-part differential. Test results are available in eight minutes.

Fujifilm and Voicebrook partner

February 2026—Fujifilm Healthcare Americas Corp. and Voicebrook are partnering to integrate Voicebrook’s VoiceOver Pro with Fujifilm’s Synapse Pathology, a picture archiving and communication system designed to streamline case management.

Octave, Quest expand access to Octave MSDA test

February 2026—Octave Bioscience is collaborating with Quest Diagnostics to make the Octave Multiple Sclerosis Disease Activity test accessible through Quest’s nationwide specimen-collection network.

Revvity launches somatic cancer reference standards

February 2026—Revvity launched highly characterized somatic cancer reference standards developed in collaboration with the Medical Device Innovation Consortium and National Institute of Standards and Technology as part of the Somatic Reference Samples Initiative.